We are vigorously defending against these claims." A Divisive Drug Dr
At 32 weeks, the semaglutide group showed significant increases in visuospatial, naming/language, and delayed recall scores compared to the placebo group (P = .01, P = .05, and P = .04, respectively)
The TRIUMPH-4 Phase 3 trial confirmed this: at 68 weeks, mean weight loss had reached 28.7% at 12 mg, an additional 4.5 percentage points beyond the 48-week Phase 2 result
The third generalizes globally
In support of this, ICV administration of GLP-1 in rats has been shown to attenuate the fasting-induced rise in NPY/AgRP expression and decreases fasting-induced inhibition of POMC/CART expression in the ARC (Seo et al., 2008)